These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35116781)

  • 1. Role of PRMT5 in bladder cancer: a comprehensive study.
    Ma Y; Zhong Y; Huang W
    Transl Cancer Res; 2019 Apr; 8(2):491-498. PubMed ID: 35116781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer.
    Liao Y; Zou X; Wang K; Wang Y; Wang M; Guo T; Zhong B; Jiang N
    J Cancer; 2021; 12(18):5605-5621. PubMed ID: 34405021
    [No Abstract]   [Full Text] [Related]  

  • 3. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
    Qin Y; Hu Q; Xu J; Ji S; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Zhang B; Yu X; Xu X
    Cell Commun Signal; 2019 Mar; 17(1):30. PubMed ID: 30922330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
    Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
    Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer.
    Tan L; Xiao K; Ye Y; Liang H; Chen M; Luo J; Qin Z
    Aging (Albany NY); 2020 May; 12(9):8728-8741. PubMed ID: 32392182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of thymosin β10 correlates with disease progression and poor prognosis in bladder cancer.
    Wang B; Wang Z; Zhang T; Yang G
    Exp Ther Med; 2019 Nov; 18(5):3759-3766. PubMed ID: 31616507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression COL10A1 promotes breast cancer progression and predicts poor prognosis.
    Zhou W; Li Y; Gu D; Xu J; Wang R; Wang H; Liu C
    Heliyon; 2022 Oct; 8(10):e11083. PubMed ID: 36281404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A panel of 8-lncRNA predicts prognosis of breast cancer patients and migration of breast cancer cells.
    Zhu L; Cui K; Weng L; Yu P; Du Y; Zhang T; Liu H; Li B; Ma W
    PLoS One; 2021; 16(6):e0249174. PubMed ID: 34086679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
    Chen YR; Li HN; Zhang LJ; Zhang C; He JG
    Front Bioeng Biotechnol; 2021; 9():645375. PubMed ID: 34124017
    [No Abstract]   [Full Text] [Related]  

  • 10. Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
    Hu G; Wang X; Han Y; Wang P
    EXCLI J; 2018; 17():1157-1166. PubMed ID: 30713476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis.
    Ding Z; Guo L; Deng Z; Li P
    Ann Hepatol; 2020; 19(3):269-279. PubMed ID: 32089501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.
    Shimizu D; Kanda M; Sugimoto H; Shibata M; Tanaka H; Takami H; Iwata N; Hayashi M; Tanaka C; Kobayashi D; Yamada S; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
    Int J Oncol; 2017 Feb; 50(2):381-386. PubMed ID: 28101581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circ-PRMT5 promotes breast cancer by the miR-509-3p/TCF7L2 axis activating the PI3K/AKT pathway.
    Wu D; Jia H; Zhang Z; Li S
    J Gene Med; 2021 Feb; 23(2):e3300. PubMed ID: 33277756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
    Jiang Y; Yuan Y; Chen M; Li S; Bai J; Zhang Y; Sun Y; Wang G; Xu H; Wang Z; Zheng Y; Nie H
    Theranostics; 2021; 11(18):9162-9176. PubMed ID: 34522232
    [No Abstract]   [Full Text] [Related]  

  • 15. PRMT5 promotes colorectal cancer growth by interaction with MCM7.
    Li X; Wang X; Zhao J; Wang J; Wu J
    J Cell Mol Med; 2021 Apr; 25(7):3537-3547. PubMed ID: 33675123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?
    Seiler R; Black PC; Thalmann G; Stenzl A; Todenhöfer T
    Urol Oncol; 2017 Jul; 35(7):458.e1-458.e7. PubMed ID: 28291637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
    Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
    Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0061140 promotes metastasis of bladder cancer through adsorbing microRNA-1236.
    Feng F; Chen AP; Wang XL; Wu GL
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5310-5319. PubMed ID: 32495864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP kinase-interacting kinase 1 (MNK1) plays as a tumor suppressor in bladder cancer.
    Chen Z; Xiao K; Zhang H; Liu C; Yang J; Liang H; Lin Z; Qin Z; Chen M; Ye Y
    Transl Cancer Res; 2020 Apr; 9(4):2588-2598. PubMed ID: 35117618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXRα/NF-κBp65 Pathway.
    Han X; Wei L; Wu B
    Onco Targets Ther; 2020; 13():3347-3357. PubMed ID: 32368093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.